Greystone Financial Group LLC lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 24.8% in the third quarter, Holdings Channel.com reports. The fund owned 1,117 shares of the pharmaceutical company’s stock after purchasing an additional 222 shares during the quarter. Greystone Financial Group LLC’s holdings in Vertex Pharmaceuticals were worth $519,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the business. Northwest Investment Counselors LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter valued at approximately $25,000. Annapolis Financial Services LLC acquired a new position in Vertex Pharmaceuticals during the first quarter worth $27,000. GHP Investment Advisors Inc. bought a new position in shares of Vertex Pharmaceuticals during the second quarter valued at $29,000. Stephens Consulting LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $31,000. Finally, Founders Capital Management grew its holdings in shares of Vertex Pharmaceuticals by 50.0% in the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock worth $35,000 after purchasing an additional 25 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Stock Performance
Shares of NASDAQ:VRTX opened at $470.05 on Thursday. The company has a 50 day moving average price of $475.60 and a two-hundred day moving average price of $461.29. Vertex Pharmaceuticals Incorporated has a 52 week low of $341.90 and a 52 week high of $510.64. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Piper Sandler increased their price target on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Truist Financial reiterated a “buy” rating and issued a $550.00 price objective (up previously from $508.00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. StockNews.com cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 5th. Finally, Guggenheim lifted their price target on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Hold” and an average target price of $492.92.
View Our Latest Analysis on Vertex Pharmaceuticals
Insider Activity
In related news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the completion of the sale, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,005 shares of company stock worth $5,988,066 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Profitably Trade Stocks at 52-Week Highs
- A $1.75 Billion Gamble: Can Lucid Ignite Growth?
- Options Trading – Understanding Strike Price
- The Rally in Lockheed Martin and RTX Can Continue: Here’s Why
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Undervalued Technology Stocks With Big Rebound Potential
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.